Expanding Collaborative Practice Agreements in Neurology Pharmacy Care

In this interview with Pharmacy Times, Ryan Fuller, PharmD, discusses how collaborative practice agreements (CPAs) at the University of Penn are currently structured within neurology, with a primary focus on multiple sclerosis and migraine management. He explains that these agreements allow pharmacists to order disease-modifying therapies and related laboratory tests under delegated physician authority. Fuller highlights plans to expand CPAs into additional disease states, including myasthenia gravis, movement disorders, and memory-related conditions. He also notes that limited pharmacist staffing within clinics remains a key barrier to broader implementation. Additionally, Fuller describes how CPAs enable pharmacists to collaborate closely with providers in selecting appropriate therapies based on clinical status and imaging results. Looking ahead, he expresses hope that expanded prescriptive authority could further strengthen the pharmacist’s role in patient-centered neurology care.